Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
Status:
Completed
Trial end date:
2004-02-12
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest dose of Tezacitabine (FMdC)
which can be safely given as a continuous infusion by vein to patients with hematologic
malignancies. The general safety and effectiveness of this drug will also be studied.